Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.47 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.44 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.41 |
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.39 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.39 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.37 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.37 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.37 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3135045 | 1.00 | MAPT (0.49) | MAPTALDH1A1MEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL5340165 | 1.00 | MAPT (0.49) | MAPTALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL7027843 | 0.98 | MAPT (0.48) | MAPTALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL8895090 | 0.98 | MAPT (0.48) | MAPTALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL8872097 | 0.98 | MAPT (0.48) | MAPTALDH1A1MEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL7020610 | 0.87 | MAPT (0.58) | MAPTALDH1A1MEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL3135048 | 0.87 | MAPT (0.58) | MAPTALDH1A1MEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL6133351 | 0.86 | MAPT (0.47) | MAPTALDH1A1MEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL1405847 | 0.86 | MAPT (0.47) | MAPTALDH1A1MEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL1405849 | 0.86 | MAPT (0.47) | MAPTALDH1A1MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5194531-A | — | — | None | — | — | JP | disclosed |
| US-7847093-B2 | Processes for the preparations of cefepime | SANDOZ AG (CH) | 2010-12-07 | — | — | US | disclosed |
| EP-2218723-A2 | Processes for the preparations of cefepime | Sandoz AG (CH) | 2010-08-18 | — | — | EP | disclosed |
| EP-1618114-B1 | PROCESSES FOR THE PREPARATIONS OF CEFEPIME | SANDOZ AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| US-20070105830-A1 | Processes for the preparations of cefepime | SANDOZ AG (CH) | 2007-05-10 | — | — | US | disclosed |
| EP-1618114-A2 | PROCESSES FOR THE PREPARATIONS OF CEFEPIME | Sandoz AG (CH) | 2006-01-25 | — | — | EP | disclosed |
| US-20050043531-A1 | Process for preparing cefepime | HANDA VIJAY KUMAR (IN) | 2005-02-24 | — | — | US | disclosed |
| WO-2004092183-A2 | PROCESSES FOR THE PREPARATIONS OF CEFEPIME | SANDOZ AG (CH) | 2004-10-28 | — | — | WO | disclosed |
| EP-0533047-B1 | Preparation of a cephalosporin antibiotic using the synisomer of a thiazolyl intermediate | BRISTOL MYERS SQUIBB CO (US) | 2003-05-07 | — | — | EP | disclosed |
| EP-0531981-B1 | Process for the preparation of a cephalosporin antibiotic | BRISTOL MYERS SQUIBB CO (US) | 2001-11-21 | — | — | EP | disclosed |
| EP-0675116-A1 | Protected aminothiazolylacetic acid derivatives | EISAI CHEMICAL CO., LTD. (JP) | 1995-10-04 | — | — | EP | disclosed |
| EP-0665847-A1 | CEPHEM COMPOUNDS, AND THEIR PHARMACEUTICAL COMPOSITIONS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-08-09 | — | — | EP | disclosed |
| WO-1994010177-A1 | CEPHEM COMPOUNDS, AND THEIR PHARMACEUTICAL COMPOSITIONS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-05-11 | — | — | WO | disclosed |
| WO-1994007898-A1 | NOVEL CEPHALOSPORIN DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 1994-04-14 | — | — | WO | disclosed |
| US-5302712-A | Intermediates for cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-04-12 | — | — | US | disclosed |
| JP-H05194531-A | PRODUCTION OF CEPHALOSPORIN ANTIBIOTIC USING SYN-ISOMER OF THIAZOLYL INTERMEDIATE | BRISTOL MYERS SQUIBB CO | 1993-08-03 | — | — | JP | disclosed |
| US-5215982-A | Antibiotics | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-06-01 | — | — | US | disclosed |
| EP-0533047-A1 | Preparation of a cephalosporin antibiotic using the synisomer of a thiazolyl intermediate | Bristol-Myers Squibb Company (US) | 1993-03-24 | — | — | EP | disclosed |
| EP-0531981-A1 | Process for the preparation of a cephalosporin antibiotic | Bristol-Myers Squibb Company (US) | 1993-03-17 | — | — | EP | disclosed |
| EP-0427248-A2 | New cephem compounds and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105830-A1 | Processes for the preparations of cefepime | CYP3A5, CYP2F1, CYP2C9 | GAA 1891/4885PTGS2 1566/4885HTR2C 3121/4885 |
| US-20050043531-A1 | Process for preparing cefepime | CPNE4, MRPL21, OTUB1 | GAA 2667/4885PTGS2 2219/4885HTR2C 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.